Bristol-Myers Squibb Company
BMYBristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban (Eliquis) for people with atrial fibrillation (30% of 2025 revenues); nivolumab (Opdivo), used to treat certain types of cancer (21% of 2025 revenues); lenalidomide (Revlimid), used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes (6% of 2025 revenues); abatacept (Orencia), used to treat autoimmune diseases such as rheumatoid arthritis (8% of 2025 revenues); pomalidomide (Pomalyst/Imnovid), an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma (6% of 2025 revenues); ipilimumab (Yervoy), to treat cancer (6% of 2025 revenues); and luspatercept (Reblozyl) for the treatment of anemia in beta thalassemia and myelodysplastic syndromes (5% of 2025 revenues). In 2025, 69% of the company's revenues came from the United States.
Drugs in Pipeline
125
Phase 3 Programs
71
Upcoming Catalysts
8
Next Catalyst
Nov 2026
Market Overview
Stock performance and key metrics
9 upcoming, 2 past
How BMY's past catalysts played out
Entecavir
Chronic Hepatitis B
Peginterferon Lambda-1a
Hepatitis C Virus
cisplatin
Head and Neck Cancer
Nivolumab
Brain Neoplasms
Cetuximab/Erbitux
Head and Neck Cancer
Imatinib
Chronic Phase Chronic Myeloid Leukemia
Ozanimod
Colitis, Ulcerative
Paclitaxel
Lung Cancer
Apixaban
Deep-Vein Thrombosis
Megestrol acetate
Anorexia
Iza-bren
Non-Small Cell Lung Cancer
Indinavir sulfate
HIV Infections
BMS-936558 (Nivolumab)
Melanoma
Topotecan
Lung Cancer
Lenalidomide
Lymphoma
Repotrectinib
Carcinoma, Non-Small-Cell Lung
Daclatasvir
Hepatitis C
Ipilimumab
Melanoma
Xanomeline and Trospium Chloride Capsules
Schizophrenia
Irbesartan
Congestive Heart Failure
Antidepressant + Aripiprazole
Major Depressive Disorder
Dacarbazine
Melanoma
Deucravacitinib
Plaque Psoriasis
Ribavirin
Hepatitis C
Nab-Paclitaxel
Non-small Cell Lung Cancer
Tanespimycin
Multiple Myeloma
Apremilast
Psoriasis
Sofosbuvir
Hepatitis C
DCV/ASV/BMS-791325
Hepatitis C
Muraglitazar
Diabetes Mellitus
stavudine extended-release, lamivudine, efavirenz
HIV Infections
Pemetrexed
Non-Small Cell Lung Cancer
Enoxaparin
Venous Thrombosis
Adalimumab
Rheumatoid Arthritis
paclitaxel (PTX)
Breast Cancer
SAR302503
Hematopoietic Neoplasm
BMS-986165
Ulcerative Colitis
Prednisone
Prostatic Neoplasms
Asunaprevir
Hepatitis C Virus Infection
Gemcitabine
Urothelial Cancer
BMS-986205
Advanced Cancer
KarXT
Bipolar-I Disorder With Mania or Mania With Mixed Features
KarX-EC
Alzheimer Disease
warfarin
Atrial Fibrillation
brivanib
Advanced Non-small Cell Lung Cancer
methotrexate
Rheumatoid Arthritis
BMS-986278
Pulmonary Fibrosis
Nivolumab/rHuPH20
Melanoma
Stavudine
AIDS Dementia Complex
Sorafenib
Hepatocellular Carcinoma
adefovir
Hepatitis B
Nivolumab and rHuPH20
Clear Cell Renal Cell Carcinoma
BMS-790052 (Daclatasvir)
Hepatitis C
Nivolumab 3 mg/kg IV
Melanoma
Abatacept
Nephrotic Syndrome
Belatacept
Kidney Transplantation
Carboplatin
Non-Small Cell Lung Cancer
mavacamten
Hypertrophic Cardiomyopathy
Entecavir (ETV)
Hepatitis B
Relatlimab
Lymphoma, Non-Hodgkin
Dasatinib
Chronic Phase Chronic Myeloid Leukemia
Cetuximab
Squamous Cell Carcinoma of the Head and Neck
BMS-986504
Pancreatic Ductal Adenocarcinoma
docetaxel
Prostate Cancer
Cyclophosphamide
Relapsed or Refractory Multiple Myeloma (RRMM)
Pumitamig
Untreated, Unresectable, or Metastatic Colorectal Cancer
NKTR-214
Melanoma
Vinflunine
Bladder Cancer
Intravenous (IV) abatacept
Rheumatoid Arthritis
BMS-986489 (BMS-986012+Nivolumab)
Extensive-Stage Small Cell Lung Cancer
Capecitabine
Breast Neoplasms
Anti-IP-10 Antibody
Colitis, Ulcerative
Rituximab
Lymphoma
CC-97540
Lupus Erythematosus, Systemic
peginterferon alfa-2a
Hepatitis C Virus
BMS-650032
Chronic Hepatitis C
Irinotecan
Metastatic Colorectal Cancer (MCRC)
MDX-010
Prostate Cancer
BMS-986177
Acute Ischemic Stroke
BMS-790052
Hepatitis C Infection
BMS-986178
Advanced Cancer
MDX-060
Hodgkin's Disease
BMS-986213
Gastric Cancer
Elotuzumab (BMS-901608; HuLuc63)
Smoldering Multiple Myeloma
BMS-770767
Dyslipidemia
Elotuzumab
Multiple Myeloma
Daratumumab
Various Advanced Cancer
CTLA4Ig / Abatacept
Psoriasis Vulgaris
Tyrosinase/gp100/MART-1 Peptides
Intraocular Melanoma
Trametinib
Colorectal Cancer
BMS-931699
Lupus
Dexamethasone
Multiple Myeloma
BMS-741672
Neuropathic Pain
BMS-690514
Breast Cancer
Ticagrelor
Coronary Artery Disease
Oral Azacitidine
Acute Myeloid Leukemia
Pomalidomide
Multiple Myeloma
HNO Donor
Heart Failure
BMS-986207
Non-Small Cell Lung Cancer
BMS-986166
Dermatitis, Atopic
BMS-823778
Diabetes Mellitus, Type 2
Pexacerfont
Major Depressive Disorder
BMS-986016
Hematologic Neoplasms
Platinum Doublet Chemotherapy
Non-Small-Cell Lung Cancer
BMS-986408
Advanced Solid Tumors
Arlocabtagene Autoleucel
Multiple Myeloma
BMS-986179
Malignant Solid Tumor
Luspatercept
Anemia
valacyclovir
Herpes Zoster
BMS-817399
Rheumatoid Arthritis
BMS-954561
Post-Herpetic Neuralgia (PHN)
BMS-791325
Chronic Hepatitis C
Cabozantinib
Advanced Renal Cell Carcinoma (RCC)
Ipilimumab+ Budesonide
Malignant Melanoma
rHuPH20
Neoplasms by Site
BMS-986158
Advanced Tumors
ipilimumab (MDX-010, BMS-734016)
Melanoma
peg-interferon alfa-2a
Hepatitis C Virus
Cobimetinib
Advanced or Metastatic Solid Tumors
BMS-582949
Rheumatoid Arthritis, NOS
Lirilumab
CANCER,NOS
BMS-986036
Hepatic Cirrhosis
MDX-1100
Ulcerative Colitis
Nivolumab (BMS-936558)
Melanoma
relatlimab+nivolumab
Melanoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Entecavir | Phase 3 | Chronic Hepatitis B | - | - |
Peginterferon Lambda-1a | Phase 3 | Hepatitis C Virus | - | - |
cisplatin | Phase 3 | Head and Neck Cancer | - | - |
Nivolumab | Phase 3 | Brain Neoplasms | - | - |
Cetuximab/Erbitux | Phase 3 | Head and Neck Cancer | - | - |
Imatinib | Phase 3 | Chronic Phase Chronic Myeloid Leukemia | - | - |
Ozanimod | Phase 3 | Colitis, Ulcerative | - | - |
Paclitaxel | Phase 3 | Lung Cancer | - | - |
Apixaban | Phase 3 | Deep-Vein Thrombosis | - | - |
Megestrol acetate | Phase 3 | Anorexia | - | - |
Iza-bren | Phase 3 | Non-Small Cell Lung Cancer | - | - |
Indinavir sulfate | Phase 3 | HIV Infections | - | - |
BMS-936558 (Nivolumab) | Phase 3 | Melanoma | - | - |
Topotecan | Phase 3 | Lung Cancer | - | - |
Lenalidomide | Phase 3 | Lymphoma | - | - |
Repotrectinib | Phase 3 | Carcinoma, Non-Small-Cell Lung | - | - |
Daclatasvir | Phase 3 | Hepatitis C | - | - |
Ipilimumab | Phase 3 | Melanoma | - | - |
Xanomeline and Trospium Chloride Capsules | Phase 3 | Schizophrenia | - | - |
Irbesartan | Phase 3 | Congestive Heart Failure | - | - |
Antidepressant + Aripiprazole | Phase 3 | Major Depressive Disorder | - | - |
Dacarbazine | Phase 3 | Melanoma | - | - |
Deucravacitinib | Phase 3 | Plaque Psoriasis | - | - |
Ribavirin | Phase 3 | Hepatitis C | - | - |
Nab-Paclitaxel | Phase 3 | Non-small Cell Lung Cancer | - | - |
Tanespimycin | Phase 3 | Multiple Myeloma | - | - |
Apremilast | Phase 3 | Psoriasis | - | - |
Sofosbuvir | Phase 3 | Hepatitis C | - | - |
DCV/ASV/BMS-791325 | Phase 3 | Hepatitis C | - | - |
Muraglitazar | Phase 3 | Diabetes Mellitus | - | - |
stavudine extended-release, lamivudine, efavirenz | Phase 3 | HIV Infections | - | - |
Pemetrexed | Phase 3 | Non-Small Cell Lung Cancer | - | - |
Enoxaparin | Phase 3 | Venous Thrombosis | - | - |
Adalimumab | Phase 3 | Rheumatoid Arthritis | - | - |
paclitaxel (PTX) | Phase 3 | Breast Cancer | - | - |
SAR302503 | Phase 3 | Hematopoietic Neoplasm | - | - |
BMS-986165 | Phase 3 | Ulcerative Colitis | - | - |
Prednisone | Phase 3 | Prostatic Neoplasms | - | - |
Asunaprevir | Phase 3 | Hepatitis C Virus Infection | - | - |
Gemcitabine | Phase 3 | Urothelial Cancer | - | - |
BMS-986205 | Phase 3 | Advanced Cancer | - | - |
KarXT | Phase 3 | Bipolar-I Disorder With Mania or Mania With Mixed Features | - | - |
KarX-EC | Phase 3 | Alzheimer Disease | - | - |
warfarin | Phase 3 | Atrial Fibrillation | - | - |
brivanib | Phase 3 | Advanced Non-small Cell Lung Cancer | - | - |
methotrexate | Phase 3 | Rheumatoid Arthritis | - | - |
BMS-986278 | Phase 3 | Pulmonary Fibrosis | - | - |
Nivolumab/rHuPH20 | Phase 3 | Melanoma | - | - |
Stavudine | Phase 3 | AIDS Dementia Complex | - | - |
Sorafenib | Phase 3 | Hepatocellular Carcinoma | - | - |
adefovir | Phase 3 | Hepatitis B | - | - |
Nivolumab and rHuPH20 | Phase 3 | Clear Cell Renal Cell Carcinoma | - | - |
BMS-790052 (Daclatasvir) | Phase 3 | Hepatitis C | - | - |
Nivolumab 3 mg/kg IV | Phase 3 | Melanoma | - | - |
Abatacept | Phase 3 | Nephrotic Syndrome | - | - |
Belatacept | Phase 3 | Kidney Transplantation | - | - |
Carboplatin | Phase 3 | Non-Small Cell Lung Cancer | - | - |
mavacamten | Phase 3 | Hypertrophic Cardiomyopathy | - | - |
Entecavir (ETV) | Phase 3 | Hepatitis B | - | - |
Relatlimab | Phase 3 | Lymphoma, Non-Hodgkin | - | - |
Dasatinib | Phase 3 | Chronic Phase Chronic Myeloid Leukemia | - | - |
Cetuximab | Phase 3 | Squamous Cell Carcinoma of the Head and Neck | - | - |
BMS-986504 | Phase 3 | Pancreatic Ductal Adenocarcinoma | - | - |
docetaxel | Phase 3 | Prostate Cancer | - | - |
Cyclophosphamide | Phase 3 | Relapsed or Refractory Multiple Myeloma (RRMM) | - | - |
Pumitamig | Phase 3 | Untreated, Unresectable, or Metastatic Colorectal Cancer | - | - |
NKTR-214 | Phase 3 | Melanoma | - | - |
Vinflunine | Phase 3 | Bladder Cancer | - | - |
Intravenous (IV) abatacept | Phase 3 | Rheumatoid Arthritis | - | - |
BMS-986489 (BMS-986012+Nivolumab) | Phase 3 | Extensive-Stage Small Cell Lung Cancer | - | - |
Capecitabine | Phase 3 | Breast Neoplasms | - | - |
Anti-IP-10 Antibody | Phase 2 | Colitis, Ulcerative | - | - |
Rituximab | Phase 2 | Lymphoma | - | - |
CC-97540 | Phase 2 | Lupus Erythematosus, Systemic | - | - |
peginterferon alfa-2a | Phase 2 | Hepatitis C Virus | - | - |
BMS-650032 | Phase 2 | Chronic Hepatitis C | - | - |
Irinotecan | Phase 2 | Metastatic Colorectal Cancer (MCRC) | - | - |
MDX-010 | Phase 2 | Prostate Cancer | - | - |
BMS-986177 | Phase 2 | Acute Ischemic Stroke | - | - |
BMS-790052 | Phase 2 | Hepatitis C Infection | - | - |
BMS-986178 | Phase 2 | Advanced Cancer | - | - |
MDX-060 | Phase 2 | Hodgkin's Disease | - | - |
BMS-986213 | Phase 2 | Gastric Cancer | - | - |
Elotuzumab (BMS-901608; HuLuc63) | Phase 2 | Smoldering Multiple Myeloma | - | - |
BMS-770767 | Phase 2 | Dyslipidemia | - | - |
Elotuzumab | Phase 2 | Multiple Myeloma | - | - |
Daratumumab | Phase 2 | Various Advanced Cancer | - | - |
CTLA4Ig / Abatacept | Phase 2 | Psoriasis Vulgaris | - | - |
Tyrosinase/gp100/MART-1 Peptides | Phase 2 | Intraocular Melanoma | - | - |
Trametinib | Phase 2 | Colorectal Cancer | - | - |
BMS-931699 | Phase 2 | Lupus | - | - |
Dexamethasone | Phase 2 | Multiple Myeloma | - | - |
BMS-741672 | Phase 2 | Neuropathic Pain | - | - |
BMS-690514 | Phase 2 | Breast Cancer | - | - |
Ticagrelor | Phase 2 | Coronary Artery Disease | - | - |
Oral Azacitidine | Phase 2 | Acute Myeloid Leukemia | - | - |
Pomalidomide | Phase 2 | Multiple Myeloma | - | - |
HNO Donor | Phase 2 | Heart Failure | - | - |
BMS-986207 | Phase 2 | Non-Small Cell Lung Cancer | - | - |
BMS-986166 | Phase 2 | Dermatitis, Atopic | - | - |
BMS-823778 | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
Pexacerfont | Phase 2 | Major Depressive Disorder | - | - |
BMS-986016 | Phase 2 | Hematologic Neoplasms | - | - |
Platinum Doublet Chemotherapy | Phase 2 | Non-Small-Cell Lung Cancer | - | - |
BMS-986408 | Phase 2 | Advanced Solid Tumors | - | - |
Arlocabtagene Autoleucel | Phase 2 | Multiple Myeloma | - | - |
BMS-986179 | Phase 2 | Malignant Solid Tumor | - | - |
Luspatercept | Phase 2 | Anemia | - | - |
valacyclovir | Phase 2 | Herpes Zoster | - | - |
BMS-817399 | Phase 2 | Rheumatoid Arthritis | - | - |
BMS-954561 | Phase 2 | Post-Herpetic Neuralgia (PHN) | - | - |
BMS-791325 | Phase 2 | Chronic Hepatitis C | - | - |
Cabozantinib | Phase 2 | Advanced Renal Cell Carcinoma (RCC) | - | - |
Ipilimumab+ Budesonide | Phase 2 | Malignant Melanoma | - | - |
rHuPH20 | Phase 2 | Neoplasms by Site | - | - |
BMS-986158 | Phase 2 | Advanced Tumors | - | - |
ipilimumab (MDX-010, BMS-734016) | Phase 2 | Melanoma | - | - |
peg-interferon alfa-2a | Phase 2 | Hepatitis C Virus | - | - |
Cobimetinib | Phase 2 | Advanced or Metastatic Solid Tumors | - | - |
BMS-582949 | Phase 2 | Rheumatoid Arthritis, NOS | - | - |
Lirilumab | Phase 2 | CANCER,NOS | - | - |
BMS-986036 | Phase 2 | Hepatic Cirrhosis | - | - |
MDX-1100 | Phase 2 | Ulcerative Colitis | - | - |
Nivolumab (BMS-936558) | Phase 2 | Melanoma | - | - |
relatlimab+nivolumab | Phase 2 | Melanoma | - | - |
Alzheimer's
1 drug in this indication
Lymphoma
1 drug in this indication
Multiple Myeloma
1 drug in this indication
Lupus Erythematosus, Systemic
1 drug in this indication
advanced melanoma
1 drug in this indication
Alzheimer's psychosis
1 drug in this indication
advanced hepatocellular carcinoma
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Bristol-Myers Squibb Company's drug pipeline?→
CatalystAlert tracks 125 drug candidates in Bristol-Myers Squibb Company's (BMY) pipeline across Phase 3, Phase 2. Its lead program is Entecavir (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Bristol-Myers Squibb Company's next FDA catalyst?→
Bristol-Myers Squibb Company's (BMY) next tracked catalyst is a Phase 3 expected November 1, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track BMY biotech catalysts?→
Add BMY to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Bristol-Myers Squibb Company's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.